This content is from: Patents

Analysis: Complexity lies ahead for CRISPR patents after PTAB decision

The eagerly-anticipated ruling from the PTAB of “no interference-in-fact” is a win for the Broad Institute in its CRISPR patent battle with University of California Berkeley. But much wrangling lies ahead over the rights to the gene-editing technology, including a potential appeal and likely licensing disputes

To access our in-house intelligence please request a trial here.

Read this article – and more – for a one-week period.

REQUEST ACCESS

Are you already an Managing IP subscriber? Login here

Instant access to all of our content. Membership Options | One Week Trial

Related